About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 810461, 14 pages
http://dx.doi.org/10.1155/2013/810461
Review Article

HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level

Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Faisalabad 38000, Pakistan

Received 18 April 2013; Accepted 9 July 2013

Academic Editor: Haruki Komatsu

Copyright © 2013 Ambreen Ayub et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C.-L. Lin and J.-H. Kao, “The clinical implications of hepatitis B virus genotype: recent advances,” Journal of Gastroenterology and Hepatology, vol. 26, no. 1, pp. 123–130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Summers, “Three recently described animal virus models for human hepatitis B virus,” Hepatology, vol. 1, no. 2, pp. 179–183, 1981. View at Scopus
  3. L. Stuyver, S. de Gendt, C. van Geyt et al., “A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness,” Journal of General Virology, vol. 81, no. 1, pp. 67–74, 2000. View at Scopus
  4. P. Arauz-Ruiz, H. Norder, B. H. Robertson, and L. O. Magnius, “Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America,” Journal of General Virology, vol. 83, no. 8, pp. 2059–2073, 2002. View at Scopus
  5. R. Viana, R. Wang, M. C. Yu, R. Welschinger, C.-Y. Chen, and M. C. Kew, “Hepatitis B viral loads in southern African blacks with hepatocellular carcinoma,” Journal of Medical Virology, vol. 81, no. 9, pp. 1525–1530, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. C. Kew, “Hepatocellular carcinoma in African Blacks: recent progress in etiology and pathogenesis,” World Journal of Hepatology, vol. 2, pp. 65–73, 2010.
  7. Mason CSaWS, “Hepatitis B virus biology,” Microbiology and Molecular Biology Reviews, vol. 64, pp. 51–68, 2000.
  8. S. Wu, T. Kanda, F. Imazeki et al., “Hepatitis B virus e antigen downregulates cytokine production in human hepatoma cell lines,” Viral Immunology, vol. 23, no. 5, pp. 467–476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Di Bisceglie, “Hepatitis B and hepatocellular carcinoma,” Hepatology, vol. 49, no. 5, pp. S56–S60, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Liu, X.-Z. Lei, L.-S. Zhao et al., “Tissue microarray for high-throughput analysis of gene expression profiles in hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 11, no. 9, pp. 1369–1372, 2005. View at Scopus
  11. D. Milich and T. J. Liang, “Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection,” Hepatology, vol. 38, no. 5, pp. 1075–1086, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Zhang, N. Torii, Z. Hu, J. Jacob, and T. J. Liang, “X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo,” Journal of Clinical Investigation, vol. 108, no. 10, pp. 1523–1531, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. Z. Hu, Z. Zhang, J. W. Kim, Y. Huang, and T. J. Liang, “Altered proteolysis and global gene expression in hepatitis B virus X transgenic mouse liver,” Journal of Virology, vol. 80, no. 3, pp. 1405–1413, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. J. Bouchard and R. J. Schneider, “The enigmatic X gene of hepatitis B virus,” Journal of Virology, vol. 78, no. 23, pp. 12725–12734, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Jiang, S. Jhunjhunwala, J. Liu et al., “The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients,” Genome Research, vol. 22, no. 4, pp. 593–601, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. D. A. Shafritz, D. Shouval, H. I. Sherman, S. J. Hadziyannis, and M. C. Kew, “Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens,” New England Journal of Medicine, vol. 305, no. 18, pp. 1067–1073, 1981. View at Scopus
  17. H. Tu, C. Bonura, C. Giannini et al., “Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues,” Cancer Research, vol. 61, no. 21, pp. 7803–7810, 2001. View at Scopus
  18. D. Kremsdorf, P. Soussan, P. Paterlini-Brechot, and C. Brechot, “Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis,” Oncogene, vol. 25, no. 27, pp. 3823–3833, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Murakami, K. Saigo, H. Takashima et al., “Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas,” Gut, vol. 54, no. 8, pp. 1162–1168, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. I.-J. Su, H.-C. Wang, H.-C. Wu, and W.-Y. Huang, “Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection,” Journal of Gastroenterology and Hepatology, vol. 23, no. 8, pp. 1169–1174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Soussan, F. Garreau, H. Zylberberg, C. Ferray, C. Brechot, and D. Kremsdorf, “In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA,” Journal of Clinical Investigation, vol. 105, no. 1, pp. 55–60, 2000. View at Scopus
  22. Z.-L. Fang, C. A. Sabin, B.-Q. Dong et al., “Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case—control study,” Journal of General Virology, vol. 89, no. 11, pp. 2882–2890, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. H.-P. Huang, H.-Y. Hsu, C.-L. Chen et al., “Pre-S2 deletions of hepatitis B virus and hepatocellular carcinoma in children,” Pediatric Research, vol. 67, no. 1, pp. 90–94, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. Y.-H. Hsieh, I.-J. Su, H.-C. Wang et al., “Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage,” Carcinogenesis, vol. 25, no. 10, pp. 2023–2032, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. H. Hsieh, I. J. Su, C. J. Yen, et al., “Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients,” Carcinogenesis, vol. 34, pp. 475–485, 2012.
  26. C. Bréchot, “Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms,” Gastroenterology, vol. 127, pp. S56–S61, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. W. N. Chen, J. Y. Chen, B. Y. Jiao et al., “Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion,” Journal of Virology, vol. 86, pp. 13533–13541, 2012. View at Publisher · View at Google Scholar
  28. G.-Y. Hwang, C.-Y. Lin, L.-M. Huang et al., “Detection of the hepatitis B virus X protein (HBx) antigen and anti-HBx antibodies in cases of human hepatocellular carcinoma,” Journal of Clinical Microbiology, vol. 41, no. 12, pp. 5598–5603, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. T. L. Gearhart and M. J. Bouchard, “The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication,” Journal of Virology, vol. 84, no. 6, pp. 2675–2686, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Dandri, P. Schirmacher, and C. E. Rogler, “Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication,” Journal of Virology, vol. 70, no. 8, pp. 5246–5254, 1996. View at Scopus
  31. M. Doria, N. Klein, R. Lucito, and R. J. Schneider, “The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors,” The EMBO Journal, vol. 14, no. 19, pp. 4747–4757, 1995. View at Scopus
  32. H. Sirma, R. Weil, O. Rosmorduc et al., “Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome,” Oncogene, vol. 16, no. 16, pp. 2051–2063, 1998. View at Scopus
  33. R. Weil, H. Sirma, C. Giannini et al., “Direct association and nuclear import of the hepatitis B virus X protein with the NF-κB inhibitor IκBα,” Molecular and Cellular Biology, vol. 19, no. 9, pp. 6345–6354, 1999. View at Scopus
  34. M. Forgues, A. J. Marrogi, E. A. Spillare et al., “Interaction of the hepatitis B virus X protein with the Crm1-dependent nuclear export pathway,” Journal of Biological Chemistry, vol. 276, no. 25, pp. 22797–22803, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. X. Zhang, H. Zhang, and L. Ye, “Effects of hepatitis B virus X protein on the development of liver cancer,” Journal of Laboratory and Clinical Medicine, vol. 147, no. 2, pp. 58–66, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Galibert, E. Mandart, F. Fitoussi, P. Tiollais, and P. Charnay, “Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli,” Nature, vol. 281, no. 5733, pp. 646–650, 1979. View at Scopus
  37. R. H. Miller and W. S. Robinson, “Common evolutionary origin of hepatitis B virus and retroviruses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 8, pp. 2531–2535, 1986. View at Scopus
  38. K. Koike, K. Moriya, H. Yotsuyanagi, S. Iino, and K. Kurokawa, “Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts,” Journal of Clinical Investigation, vol. 94, no. 1, pp. 44–49, 1994. View at Scopus
  39. H. Nakatake, O. Chisaka, S. Yamamoto, K. Matsubara, and R. Koshy, “Effect of X protein on transactivation of hepatitis B virus promoters and on viral replication,” Virology, vol. 195, no. 2, pp. 305–314, 1993. View at Publisher · View at Google Scholar · View at Scopus
  40. D. F. Spandau and C.-H. Lee, “Trans-activation of viral enhancers by the hepatitis B virus X protein,” Journal of Virology, vol. 62, no. 2, pp. 427–434, 1988. View at Scopus
  41. J.-S. Twu, K. Chu, and W. S. Robinson, “Hepatitis B virus X gene activates κB-like enhancer sequences in the long terminal repeat of human immunodeficiency virus 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 13, pp. 5168–5172, 1989. View at Scopus
  42. P. Zahm, P. H. Hofschneider, and R. Koshy, “The HBV X-ORF encodes a transactivator: a potential factor in viral hepatocarcinogenesis,” Oncogene, vol. 3, no. 2, pp. 169–177, 1988. View at Scopus
  43. H.-S. Chen, S. Kaneko, R. Girones et al., “The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks,” Journal of Virology, vol. 67, no. 3, pp. 1218–1226, 1993. View at Scopus
  44. A. S. Kekule, U. Lauer, L. Weiss, B. Luber, and P. H. Hofschneider, “Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway,” Nature, vol. 361, no. 6414, pp. 742–745, 1993. View at Publisher · View at Google Scholar · View at Scopus
  45. C.-M. Kim, K. Koike, I. Saito, T. Miyamura, and G. Jay, “HBx gene of hepatitis B virus induces liver cancer in transgenic mice,” Nature, vol. 351, no. 6324, pp. 317–320, 1991. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Koike, K. Moriya, S. Iino et al., “High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice,” Hepatology, vol. 19, no. 4, pp. 810–819, 1994. View at Publisher · View at Google Scholar · View at Scopus
  47. A. M. Moriarty, H. Alexander, R. A. Lerner, and G. B. Thornton, “Antibodies to peptides detect new hepatitis B antigen: serological correlation with hepatocellular carcinoma,” Science, vol. 227, no. 4685, pp. 429–433, 1985. View at Scopus
  48. M. T. Rossner, “Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator,” Journal of Medical Virology, vol. 36, no. 2, pp. 101–117, 1992. View at Scopus
  49. E. Seto, P. J. Mitchell, and T. S. Benedict Yen, “Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors,” Nature, vol. 344, no. 6261, pp. 72–74, 1990. View at Scopus
  50. Y. Shirakata, M. Kawada, Y. Fujiki et al., “The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells,” Japanese Journal of Cancer Research, vol. 80, no. 7, pp. 617–621, 1989. View at Scopus
  51. N. Li, S. I. Grivennikov, and M. Karin, “The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment,” Cancer Cell, vol. 19, no. 4, pp. 429–431, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. T. L. Gearhart and M. J. Bouchard, “The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication,” Journal of Virology, vol. 84, no. 6, pp. 2675–2686, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. B. Yang and M. J. Bouchard, “The hepatitis B virus X protein elevates cytosolic calcium signals by modulating mitochondrial calcium uptake,” Journal of Virology, vol. 86, no. 1, pp. 313–327, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. M. J. Bouchard and R. J. Schneider, “The enigmatic X gene of hepatitis B virus,” Journal of Virology, vol. 78, no. 23, pp. 12725–12734, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. J.-H. Cheong, M.-K. Yi, Y. Lin, and S. Murakami, “Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation,” The EMBO Journal, vol. 14, no. 1, pp. 143–150, 1995. View at Scopus
  56. I. Haviv, M. Shamay, G. Doitsh, and Y. Shaul, “Hepatitis B virus pX targets TFIIB in transcription coactivation,” Molecular and Cellular Biology, vol. 18, no. 3, pp. 1562–1569, 1998. View at Scopus
  57. Y. Lin, T. Nomura, J. Cheong, D. Dorjsuren, K. Iida, and S. Murakami, “Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5,” Journal of Biological Chemistry, vol. 272, no. 11, pp. 7132–7139, 1997. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Murakami, J. Cheong, S. Ohno, K. Matsushima, and S. Kaneko, “Transactivation of human hepatitis B virus X protein, HBx, operates through a mechanism distinct from protein kinase C and okadaic acid activation pathways,” Virology, vol. 199, no. 1, pp. 243–246, 1994. View at Publisher · View at Google Scholar · View at Scopus
  59. B. H. C. Byung Hyune Choi, M. Choi, H. Y. J. Hyun Yong Jeon, and H. M. R. Hyune Mo Rho, “Hepatitis B viral X protein overcomes inhibition of E2F1 activity by pRb on the human Rb gene promoter,” DNA and Cell Biology, vol. 20, no. 2, pp. 75–80, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. I. Qadri, J. W. Conaway, R. C. Conaway, J. Schaack, and A. Siddiqui, “Hepatitis B virus transactivator protein, HBx, associates with the components of TFIIH and stimulates the DNA helicase activity of TFIIH,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 20, pp. 10578–10583, 1996. View at Publisher · View at Google Scholar · View at Scopus
  61. L. W. Elmore, A. R. Hancock, S.-F. Chang et al., “Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 26, pp. 14707–14712, 1997. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Pan, L.-X. Duan, B. S. Sun, and M. A. Feitelson, “Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF-κB,” Journal of General Virology, vol. 82, no. 1, pp. 171–182, 2001. View at Scopus
  63. M. Nicolas, A. Wolfer, K. Raj et al., “Notch1 functions as a tumor suppressor in mouse skin,” Nature Genetics, vol. 33, no. 3, pp. 416–421, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. C.-T. Yeh, “Hepatitis B virus X protein: searching for a role in hepatocarcinogenesis,” Journal of Gastroenterology and Hepatology, vol. 15, no. 4, pp. 339–341, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. K.-H. Lim, K.-H. Kim, S. I. Choi et al., “RPS3a over-expressed in HBV-associated hepatocellular carcinoma enhances the HBx-induced NF-κB signaling via its novel chaperoning function,” PLoS ONE, vol. 6, no. 8, Article ID e22258, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. W.-L. Shih, M.-L. Kuo, S.-E. Chuang, A.-L. Cheng, and S.-L. Doong, “Hepatitis b virus x protein inhibits transforming growth factor-β-induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway,” Journal of Biological Chemistry, vol. 275, no. 33, pp. 25858–25864, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. Y.-H. Lee and Y. Yun, “HBx protein of hepatitis B virus activates Jak1-STAT signaling,” Journal of Biological Chemistry, vol. 273, no. 39, pp. 25510–25515, 1998. View at Publisher · View at Google Scholar · View at Scopus
  68. T.-W. Chung, Y.-C. Lee, and C.-H. Kim, “Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential,” The FASEB Journal, vol. 18, no. 10, pp. 1123–1125, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. C.-T. Bock, N. L. Toan, B. Koeberlein et al., “Subcellular mislocalization of mutant hepatitis B X proteins contributes to modulation of stat/socs signaling in hepatocellular carcinoma,” Intervirology, vol. 51, no. 6, pp. 432–443, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. Q. Sun, Y. Wang, Y. Zhang et al., “Expression profiling reveals dysregulation of cellular cytoskeletal genes in HBx-induced hepatocarcinogenesis,” Cancer Biology & Therapy, vol. 6, no. 5, pp. 668–674, 2007. View at Scopus
  71. S.-W. Lee, Y. M. Lee, S.-K. Bae, S. Murakami, Y. Yun, and K.-W. Kim, “Human hepatitis B virus x protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis,” Biochemical and Biophysical Research Communications, vol. 268, no. 2, pp. 456–461, 2000. View at Publisher · View at Google Scholar · View at Scopus
  72. Y.-G. Yoo, T.-Y. Na, H.-W. Seo et al., “Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells,” Oncogene, vol. 27, no. 24, pp. 3405–3413, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Xu, H. Liu, L. Chen et al., “Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1,” Gastroenterology, vol. 143, pp. 199–212, 2012. View at Publisher · View at Google Scholar
  74. H. B. El-Serag and K. L. Rudolph, “Hepatocellular carcinoma: epidemiology and molecular carcinogenesis,” Gastroenterology, vol. 132, no. 7, pp. 2557–2576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. D. Poon, B. O. Anderson, L.-T. Chen et al., “Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009,” The Lancet Oncology, vol. 10, no. 11, pp. 1111–1118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. G. Montalto, M. Cervello, L. Giannitrapani, F. Dantona, A. Terranova, and L. A. M. Castagnetta, “Epidemiology, risk factors, and natural history of hepatocellular carcinoma,” Annals of the New York Academy of Sciences, vol. 963, pp. 13–20, 2002. View at Scopus
  77. A. I. Gomaa, S. A. Khan, M. B. Toledano, I. Waked, and S. D. Taylor-Robinson, “Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis,” World Journal of Gastroenterology, vol. 14, no. 27, pp. 4300–4308, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. A. G. Weinberg, C. E. Mize, and H. G. Worthen, “The occurence of hepatoma in the chronic form of hereditary tyrosinemia,” Journal of Pediatrics, vol. 88, no. 3, pp. 434–438, 1976. View at Scopus
  79. E. Hashimoto, S. Yatsuji, M. Tobari et al., “Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis,” Journal of Gastroenterology, vol. 44, no. 19, pp. 89–95, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. T. A. Dragani, “Risk of HCC: genetic heterogeneity and complex genetics,” Journal of Hepatology, vol. 52, no. 2, pp. 252–257, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. H. B. El-Serag, T. Tran, and J. E. Everhart, “Diabetes Increases the Risk of Chronic Liver Disease and Hepatocellular Carcinoma,” Gastroenterology, vol. 126, no. 2, pp. 460–468, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. C. Gao, H.-C. Zhao, J.-T. Li, and S.-K. Yao, “Diabetes mellitus and hepatocellular carcinoma: comparison of Chinese patients with and without HBV-related cirrhosis,” World Journal of Gastroenterology, vol. 16, no. 35, pp. 4467–4475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. E. J. Park, J. H. Lee, G.-Y. Yu et al., “Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression,” Cell, vol. 140, no. 2, pp. 197–208, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Yoshida, H. Nakamura, Y. Okuda et al., “Expression of hepatoma-derived growth factor in hepatocarcinogenesis,” Journal of Gastroenterology and Hepatology, vol. 18, no. 11, pp. 1293–1301, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. K. V. Kowdley, “Iron, hemochromatosis, and hepatocellular carcinoma,” Gastroenterology, vol. 127, pp. S79–S86, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. J.-H. Hung, Y.-N. Teng, L. H.-C. WangLily et al., “Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells,” PLoS ONE, vol. 6, no. 12, article e28977, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Wang, J. Huang, M. Jiang, and L. Sun, “Survivin (BIRC5) cell cycle computational network in human no-tumor hepatitis/cirrhosis and hepatocellular carcinoma transformation,” Journal of Cellular Biochemistry, vol. 112, no. 5, pp. 1286–1294, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. M. A. Patil, S. A. Lee, E. Macias et al., “Role of cyclin D1 as a mediator of c-Met- and B-catenin-induced hepatocarcinogenesis,” Cancer Research, vol. 69, no. 1, pp. 253–261, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. C.-F. Lee, Z.-Q. Ling, T. Zhao, and K.-R. Lee, “Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 14, no. 39, pp. 6072–6077, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Kim, H. C. Lee, O. Tsedensodnom et al., “Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/β-catenin signaling pathway in hepatocellular carcinoma cells,” Journal of Hepatology, vol. 48, no. 5, pp. 780–791, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. N. Iizuka, M. Oka, T. Tamesa, Y. Hamamoto, and H. Yamada-Okabe, “Imbalance in expression levels of insulin-like growth factor 2 and H19 transcripts linked to progression of hepatocellular carcinoma,” Anticancer Research, vol. 24, no. 6, pp. 4085–4089, 2004. View at Scopus
  92. K. Migita, S. Miyazoe, Y. Maeda et al., “Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection—association between TGF-β1 polymorphisms and hepatocellular carcinoma,” Journal of Hepatology, vol. 42, no. 4, pp. 505–510, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Zhang, W.-L. Wang, Q. Li, and Q. Qiao, “Expression of transforming growth factor-α and hepatitis B surface antigen in human hepatocellular carcinoma tissues and its significance,” World Journal of Gastroenterology, vol. 10, no. 6, pp. 830–833, 2004. View at Scopus
  94. X. Tian, J. Li, Z.-M. Ma, C. Zhao, D.-F. Wan, and Y.-M. Wen, “Role of hepatitis B surface antigen in the development of hepatocellular carcinoma: regulation of lymphoid enhancer-binding factor 1,” Journal of Experimental & Clinical Cancer Research, vol. 28, no. 1, article 58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. Y. He, H. Zhang, J. Yin et al., “IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C,” Carcinogenesis, vol. 30, no. 11, pp. 1916–1922, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Tanaka and J. R. Wands, “Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor β1-induced apoptosis,” Cancer Research, vol. 56, no. 15, pp. 3391–3394, 1996. View at Scopus
  97. L. Segat, M. Milanese, and S. Crovella, “Pin1 promoter polymorphisms in hepatocellular carcinoma patients,” Gastroenterology, vol. 132, no. 7, pp. 2618–2619, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. T. Maass, I. Sfakianakis, F. Staib, M. Krupp, P. R. Galle, and A. Teufel, “Microarray-based gene expression analysis of hepatocellular carcinoma,” Current Genomics, vol. 11, no. 4, pp. 261–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. M. D. Berzsenyi, S. K. Roberts, and M. R. Beard, “Genomics of hepatitis B and C infections: diagnostic and therapeutic applications of microarray profiling,” Antiviral Therapy, vol. 11, no. 5, pp. 541–552, 2006. View at Scopus
  100. A. Teufel, F. Staib, S. Kanzler, A. Weinmann, H. Schulze-Bergkamen, and P. R. Galle, “Genetics of hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 13, no. 16, pp. 2271–2282, 2007. View at Scopus
  101. M.-Y. Cha, C.-M. Kim, Y.-M. Park, and W.-S. Ryu, “Hepatitis B virus X protein is essential for the activation of Wnt/β-catenin signaling in hepatoma cells,” Hepatology, vol. 39, no. 6, pp. 1683–1693, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. H. L. A. Janssen, H. Higuchi, A. Abdulkarim, and G. J. Gores, “Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression,” Journal of Hepatology, vol. 39, no. 3, pp. 414–420, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. X. Zhang, N. Dong, L. Yin et al., “Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues,” Journal of Medical Virology, vol. 77, no. 3, pp. 374–381, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. J.-W. Lu, Y. Hsia, W.-Y. Yang et al., “Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model,” Carcinogenesis, vol. 33, no. 1, pp. 209–219, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Ali, M. Idrees, L. Ali et al., “Hepatitis B virus in Pakistan: a systematic review of prevalence, risk factors, awareness status and genotypes,” Virology Journal, vol. 8, article 102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. G. G. Chen, P. B. S. Lai, P. K. S. Chan et al., “Decreased expression of Bid in human hepatocellular carcinoma is related to hepatitis B virus X protein,” European Journal of Cancer, vol. 37, no. 13, pp. 1695–1702, 2001. View at Publisher · View at Google Scholar · View at Scopus
  107. Z.-J. Wu, Y. Zhu, D.-R. Huang, and Z.-Q. Wang, “Constructing the HBV-human protein interaction network to understand the relationship between HBV and hepatocellular carcinoma,” Journal of Experimental and Clinical Cancer Research, vol. 29, no. 1, article 146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. C.-M. Wong, J. M.-F. Lee, Y.-P. Ching, D.-Y. Jin, and I. O.-L. Ng, “Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma,” Cancer Research, vol. 63, no. 22, pp. 7646–7651, 2003. View at Scopus
  109. Z. Peng, Y. Zhang, W. Gu et al., “Integration of the hepatitis B virus X fragment in hepatocellular carcinoma and its effects on the expression of multiple molecules: a key to the cell cycle and apoptosis,” International Journal of Oncology, vol. 26, no. 2, pp. 467–473, 2005. View at Scopus
  110. Y. Gong, L. Cui, and G. Y. Minuk, “The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma,” Molecular and Cellular Biochemistry, vol. 207, no. 1-2, pp. 101–104, 2000. View at Scopus
  111. H. Li, C. Ge, F. Zhao et al., “Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinoma,” Hepatology, vol. 54, no. 3, pp. 910–919, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. S. S. Choi, A. Omenetti, W.-K. Syn, and A. M. Diehl, “The role of Hedgehog signaling in fibrogenic liver repair,” International Journal of Biochemistry & Cell Biology, vol. 43, no. 2, pp. 238–244, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. K. Yuan, Z. Lian, B. Sun, M. M. Clayton, I. O. L. Ng, and M. A. Feitelson, “Role of mir-148a in hepatitis B associated hepatocellular carcinoma,” PLoS ONE, vol. 7, no. 4, article e35331, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. S. J. Moghaddam, E. N. Haghighi, S. Samiee et al., “Immunohistochemical analysis of p53, cyclinD1, RB1, c-fos and N-ras gene expression in hepatocellular carcinoma in Iran,” World Journal of Gastroenterology, vol. 13, no. 4, pp. 588–593, 2007. View at Scopus
  115. L. Yao, F. J. Li, Z. Q. Tang, S. Gao, and Q. Q. Wu, “Smad4 expression in hepatocellular carcinoma differs by hepatitis status,” Asian Pacific Journal of Cancer Prevention, vol. 13, pp. 1297–1303, 2012. View at Publisher · View at Google Scholar
  116. P.-Y. Chu, C.-M. Yeh, N. C. Hsu, Y.-S. Chang, J.-G. Chang, and K.-T. Yeh, “Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma,” Swiss Medical Weekly, vol. 140, article w13065, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. H. Nakagawa and S. Maeda, “Inflammation- and stress-related signaling pathways in hepatocarcinogenesis,” World Journal of Gastroenterology, vol. 18, pp. 4071–4081, 2012. View at Publisher · View at Google Scholar
  118. T. Mamiya, K. Yamazaki, Y. Masugi et al., “Reduced transforming growth factor-β receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis,” Laboratory Investigation, vol. 90, no. 9, pp. 1339–1345, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. A. Csepregi, M. P. A. Ebert, C. Röcken et al., “Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma,” BMC Cancer, vol. 10, Article ID 3171471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. Y. W. Hong and J. Ding, “Molecular signaling in hepatocellular carcinoma,” Cancer Genetics, vol. 8, pp. 337–348, 2011. View at Publisher · View at Google Scholar
  121. J. Haybaeck, N. Zeller, M. J. Wolf et al., “A lymphotoxin-driven pathway to hepatocellular carcinoma,” Cancer Cell, vol. 16, no. 4, pp. 295–308, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. M. A. Sameh and R. He, “Liver cancer stem cells,” International Journal of Hepatology, vol. 2011, pp. 1–5, 2011.
  123. N. C. Teoh, “Pre-“EMT”ing key processes in liver carcinogenesis: growing evidence for how malignant hepatocytes invade and conquer: commentary,” Hepatology, vol. 52, no. 1, pp. 384–388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. V. W.-S. Wong, J. Yu, A. S.-L. Cheng et al., “High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B,” International Journal of Cancer, vol. 124, no. 12, pp. 2766–2770, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Arzumanyan, V. Sambandam, M. Clayton et al., “Hedgehog signaling blockade delays hepatocarcinogenesis induced by Hepatitis B virus X protein (HBx),” Cancer Research, vol. 72, no. 22, pp. 5912–5920, 2012. View at Publisher · View at Google Scholar
  126. C.-J. Yen, Y.-J. Lin, C.-S. Yen et al., “Hepatitis B virus X protein upregulates mTOR signalingthrough IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma,” PLoS One, vol. 7, article e41931, 2012.
  127. C. Coulouarn, V. M. Factor, E. A. Conner, and S. S. Thorgeirsson, “Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer,” Carcinogenesis, vol. 32, no. 10, pp. 1434–1440, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. R.-H. Fan, J. Li, N. Wu, and P.-S. Chen, “Late SV40 factor: a key mediator of Notch signaling in human hepatocarcinogenesis,” World Journal of Gastroenterology, vol. 17, no. 29, pp. 3420–3430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  129. Y. Qin, J.-Y. Liu, B. Li, Z.-L. Sun, and Z.-F. Sun, “Association of low p16INK4a and p15INK4b mRNAs expression with their CpG islands methylation with human hepatocellular carcinogenesis,” World Journal of Gastroenterology, vol. 10, no. 9, pp. 1276–1280, 2004. View at Scopus
  130. T. Severi, C. Ying, J. R. Vermeesch et al., “Hepatitis B virus replication causes oxidative stress in HepAD38 liver cells,” Molecular and Cellular Biochemistry, vol. 290, no. 1-2, pp. 79–85, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. M.-W. Yu, S.-Y. Yang, I.-J. Pan et al., “Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma,” Journal of the National Cancer Institute, vol. 95, no. 19, pp. 1485–1488, 2003. View at Scopus
  132. M. Kim, H. C. Lee, O. Tsedensodnom et al., “Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/β-catenin signaling pathway in hepatocellular carcinoma cells,” Journal of Hepatology, vol. 48, no. 5, pp. 780–791, 2008. View at Publisher · View at Google Scholar · View at Scopus
  133. S. Wieland, R. Thimme, R. H. Purcell, and F. V. Chisari, “Genomic analysis of the host response to hepatitis B virus infection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 17, pp. 6669–6674, 2004. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Gordon, “Alternative activation of macrophages,” Nature Reviews Immunology, vol. 3, pp. 23–35, 2003. View at Publisher · View at Google Scholar
  135. P. R. Taylor, L. Martinez-Pomares, M. Stacey, H.-H. Lin, G. D. Brown, and S. Gordon, “Macrophage receptors and immune recognition,” Annual Review of Immunology, vol. 23, pp. 901–944, 2005. View at Publisher · View at Google Scholar · View at Scopus
  136. G. Kolios, V. Valatas, and E. Kouroumalis, “Role of Kupffer cells in the pathogenesis of liver disease,” World Journal of Gastroenterology, vol. 12, no. 46, pp. 7413–7420, 2006. View at Scopus
  137. V. A. Bohr and G. L. Dianov, “Oxidative DNA damage processing in nuclear and mitochondrial DNA,” Biochimie, vol. 81, no. 1-2, pp. 155–160, 1999. View at Publisher · View at Google Scholar · View at Scopus
  138. G. Waris and H. Ahsan, “Reactive oxygen species: role in the development of cancer and various chronic conditions,” Journal of Carcinogenesis, vol. 5, article14, 2006. View at Publisher · View at Google Scholar · View at Scopus
  139. M. Senba, T. Nakamura, and H. Itakura, “Statistical analysis of relationship between iron accumulation and hepatitis B surface antigen,” American Journal of Clinical Pathology, vol. 84, no. 3, pp. 340–342, 1985. View at Scopus
  140. R. Gonzalez-Amaro, C. Garcia-Monzon, L. Garcia-Buey et al., “Induction of tumor necrosis factor α production by human hepatocytes in chronic viral hepatitis,” Journal of Experimental Medicine, vol. 179, no. 3, pp. 841–848, 1994. View at Scopus
  141. G. Jia, R. Takahashi, Z. Zhang, Y. Tsuji, and H. Sone, “Aldo-keto reductase 1 family B7 is the gene induced in response to oxidative stress in the livers of Long-Evans Cinnamon rats,” International Journal of Oncology, vol. 29, no. 4, pp. 829–838, 2006. View at Scopus
  142. T. M. Forte, M. R. McCall, B. B. Knowles, and V. G. Shore, “Isolation and characterization of lipoproteins produced by human hepatoma-derived cell lines other than HepG2,” The Journal of Lipid Research, vol. 30, no. 6, pp. 817–829, 1989. View at Scopus
  143. L. W. J. Klomp, S.-J. Lin, D. S. Yuan, R. D. Klausner, V. C. Culotta, and J. D. Gitlin, “Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis,” Journal of Biological Chemistry, vol. 272, no. 14, pp. 9221–9226, 1997. View at Publisher · View at Google Scholar · View at Scopus
  144. Entrez Gene: aTOX1 ATX1 antioxidant protein 1 homolog (yeast).
  145. W. Liu, S. S. Baker, R. D. Baker, N. J. Nowak, and L. Zhu, “Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis,” PLoS ONE, vol. 6, no. 9, article e24363, 2011. View at Publisher · View at Google Scholar · View at Scopus
  146. S. Boyault, D. S. Rickman, A. De Reyniès et al., “Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets,” Hepatology, vol. 45, no. 1, pp. 42–52, 2007. View at Publisher · View at Google Scholar · View at Scopus
  147. R. N. Aravalli, C. J. Steer, and E. N. K. Cressman, “Molecular mechanisms of hepatocellular carcinoma,” Hepatology, vol. 48, no. 6, pp. 2047–2063, 2008. View at Publisher · View at Google Scholar · View at Scopus
  148. T. Yuan, J. Wei, J. Luo, M. Liu, S. Deng, and P. Chen, “Polymorphisms of base-excision repair genes hOGG1 326cys and XRCC1 280His increase hepatocellular carcinoma risk,” Digestive Diseases and Sciences, vol. 57, pp. 2451–2457, 2012. View at Publisher · View at Google Scholar · View at Scopus
  149. S. Phillips, S. Chokshi, A. Riva, A. Evans, R. Williams, and N. V. Naoumov, “CD8+ T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions,” Journal of Immunology, vol. 184, no. 1, pp. 287–295, 2010. View at Publisher · View at Google Scholar · View at Scopus
  150. M. K. Maini, C. Boni, C. K. Lee et al., “The role of virus-specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus infection,” Journal of Experimental Medicine, vol. 191, no. 8, pp. 1269–1280, 2000. View at Publisher · View at Google Scholar · View at Scopus
  151. G. Sitia, R. Aiolfi, P. Di Lucia et al., “Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, pp. E2165–E2172, 2012. View at Publisher · View at Google Scholar
  152. J. Wang, W. Zhao, L. Cheng et al., “CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice,” Journal of Immunology, vol. 185, no. 12, pp. 7654–7662, 2010. View at Publisher · View at Google Scholar · View at Scopus
  153. T. M. Welzel, B. I. Graubard, S. Zeuzem, H. B. El-Serag, J. A. Davila, and K. A. Mcglynn, “Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-medicare database,” Hepatology, vol. 54, no. 2, pp. 463–471, 2011. View at Publisher · View at Google Scholar · View at Scopus
  154. G. L.-H. Wong, V. W.-S. Wong, P. C.-L. Choi et al., “Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B,” Gut, vol. 58, no. 1, pp. 111–117, 2009. View at Publisher · View at Google Scholar · View at Scopus
  155. V. Paradis, S. Zalisnski, E. Chelbi et al., “Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liverfibrosis: a pathological analysis,” Hepatology, vol. 49, no. 3, pp. 851–859, 2009. View at Publisher · View at Google Scholar · View at Scopus
  156. F. Cauchy, S. Zalinski, S. Dokmak et al., “Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome,” British Journal of Surgery, vol. 100, pp. 113–121, 2013. View at Publisher · View at Google Scholar
  157. F. Turati, R. Talamini, C. Pelucchi et al., “Metabolic syndrome and hepatocellular carcinoma risk,” British Journal of Cancer, vol. 108, pp. 222–228, 2013. View at Publisher · View at Google Scholar
  158. B. Werle-Lapostolle, S. Bowden, S. Locarnini et al., “Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy,” Gastroenterology, vol. 126, no. 7, pp. 1750–1758, 2004. View at Publisher · View at Google Scholar · View at Scopus
  159. A. Laras, J. Koskinas, E. Dimou, A. Kostamena, and S. J. Hadziyannis, “Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients,” Hepatology, vol. 44, no. 3, pp. 694–702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  160. T. M. Abraham and D. D. Loeb, “The topology of hepatitis B virus pregenomic RNA promotes its replication,” Journal of Virology, vol. 81, no. 21, pp. 11577–11584, 2007. View at Publisher · View at Google Scholar · View at Scopus
  161. C.-L. Chong, M.-L. Chen, Y.-C. Wu et al., “Dynamics of HBV cccDNA expression and transcription in different cell growth phase,” Journal of Biomedical Science, vol. 18, no. 1, article 96, 2011. View at Publisher · View at Google Scholar · View at Scopus
  162. K. Wursthorn, M. Lutgehetmann, M. Dandri et al., “Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B,” Hepatology, vol. 44, no. 3, pp. 675–684, 2006. View at Publisher · View at Google Scholar · View at Scopus
  163. H. L.-Y. Chan, V. W.-S. Wong, A. M.-L. Tse et al., “Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response,” Clinical Gastroenterology and Hepatology, vol. 5, no. 12, pp. 1462–1468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. F. van Bömmel, B. Zöllner, C. Sarrazin et al., “Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy,” Hepatology, vol. 44, no. 2, pp. 318–325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  165. T. Hosaka, F. Suzuki, M. Kobayashi et al., “HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy,” Liver International, vol. 30, no. 10, pp. 1461–1470, 2010. View at Publisher · View at Google Scholar · View at Scopus
  166. “Liver EAftSot: novel therapeutic approaches may cure chronic HBV infection,” in Novel Therapeutic Approaches May Cure Chronic HBV Infection, ScienceDaily, Rockville, Md, USA, 2013.
  167. S.-M. Lin, C.-J. Lin, C.-W. Hsu et al., “Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors,” Cancer, vol. 100, no. 2, pp. 376–382, 2004. View at Publisher · View at Google Scholar · View at Scopus
  168. M. G. Peters, H. W. Hann, P. Martin et al., “Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B,” Gastroenterology, vol. 126, no. 1, pp. 91–101, 2004. View at Publisher · View at Google Scholar · View at Scopus
  169. S. K. Fung, P. Andreone, S. H. Han et al., “Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation,” Journal of Hepatology, vol. 43, no. 6, pp. 937–943, 2005. View at Publisher · View at Google Scholar · View at Scopus
  170. H. Huynh, “Molecularly targeted therapy in hepatocellular carcinoma,” Biochemical Pharmacology, vol. 80, no. 5, pp. 550–560, 2010. View at Publisher · View at Google Scholar · View at Scopus
  171. A. Villanueva and J. M. Llovet, “Targeted therapies for hepatocellular carcinoma,” Gastroenterology, vol. 140, no. 5, pp. 1410–1426, 2011. View at Publisher · View at Google Scholar · View at Scopus
  172. C. Frenette and R. Gish, “Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications,” World Journal of Gastroenterology, vol. 18, no. 6, pp. 498–506, 2012. View at Publisher · View at Google Scholar · View at Scopus
  173. P. J. Johnson, “Non-surgical treatment of hepatocellular carcinoma,” HPB, vol. 7, no. 1, pp. 50–55, 2005. View at Publisher · View at Google Scholar · View at Scopus
  174. S. A. Curley, K. E. Stuart, J. M. Schwartz, and R. L. Carithers, Nonsurgical Therapies for Localized Hepatocellular Carcinoma: Radiofrequency Ablation, Percutaneous Ethanol Injection, Thermal Ablation, and Cryoablation, Wolters Kluwer Health, Baltimore, Md, USA, 2012.
  175. S. A. Curley, K. E. Stuart, J. M. Schwartz, and R. L. Carithers, Nonsurgical Therapies for Localized Hepatocellular Carcinoma: Radiofrequency Ablation, Percutaneous Ethanol Injection, Thermal Ablation, and cryoablation, Wolters Kluwer Health Solution, Baltimore, Md, USA, 2013.
  176. K. Madalinski, “Recent advances in hepatitis B vaccination,” Hepatitis B Annual, vol. 5, no. 1, pp. 51–65, 2008. View at Publisher · View at Google Scholar · View at Scopus